Treatment of Asymptomatic Mycoplasma genitalium and Mycoplasma hominis in Males
Do not treat asymptomatic males who test positive for Mycoplasma genitalium or Mycoplasma hominis. Treatment should be reserved for symptomatic patients only, given the high rates of spontaneous clearance, increasing antimicrobial resistance, and lack of evidence supporting screening or treatment of asymptomatic infections in men.
Key Evidence Supporting Conservative Management
Mycoplasma genitalium in Asymptomatic Men
Most asymptomatic M. genitalium infections resolve spontaneously without treatment. Studies show that 30% of asymptomatic infections clear without intervention, and most men likely resolve infection without developing disease 1, 2.
Current guidelines explicitly recommend against screening asymptomatic men. The 2021 European guideline states that symptoms are the main indication for diagnostic testing, and in the absence of randomized controlled trials demonstrating cost-effectiveness, screening of asymptomatic men cannot be recommended 3, 1.
The CDC recognizes M. genitalium as an established STI requiring treatment when detected, but this recommendation applies to symptomatic patients or those with confirmed urethritis 4.
Critical Antimicrobial Resistance Concerns
Macrolide resistance is now extremely high, with 73% of M. genitalium strains showing resistance to azithromycin in recent studies 2.
Treating asymptomatic infections contributes to antimicrobial resistance without clear clinical benefit, as the cure rate with first-line azithromycin therapy is only 30-40% overall and 35% for anorectal infections 3, 5.
Moxifloxacin resistance is also increasing, making preservation of effective antibiotics critical 3, 2.
Mycoplasma hominis Considerations
M. hominis is not considered a sexually transmitted pathogen requiring treatment in asymptomatic men. It is part of normal genital flora and is associated with bacterial vaginosis in women but does not cause urethritis in men 6.
M. hominis is not mentioned in any STI treatment guidelines for men, as it lacks pathogenic significance in the male genitourinary tract 7, 8, 9.
When Treatment IS Indicated
Symptomatic M. genitalium Infection
Treat when urethritis symptoms are present: dysuria, urethral discharge, or objective evidence of urethral inflammation (≥5 WBC per high-power field on urethral Gram stain or ≥10 WBC per high-power field in first-void urine) 8, 3.
First-line therapy for macrolide-susceptible strains: Azithromycin 500 mg orally on day 1, then 250 mg orally daily on days 2-5 4, 3.
Second-line therapy for macrolide-resistant strains: Moxifloxacin 400 mg orally once daily for 7 days (14 days for complicated infections like epididymitis) 4, 3.
Essential Partner Management (Only for Treated Patients)
All sexual partners within the preceding 60 days must be evaluated and treated simultaneously, regardless of their symptom status, to prevent reinfection 4.
Both patient and partners must abstain from sexual intercourse for 7 days after completing single-dose therapy or until completion of multi-day regimens 8, 4.
Common Pitfalls to Avoid
Do not treat based solely on positive testing without symptoms. This increases antimicrobial resistance and provides no proven benefit 3, 1.
Do not assume all positive M. genitalium tests require treatment. The high rate of asymptomatic carriage and spontaneous clearance argues against universal treatment 1, 2.
Do not use azithromycin 1g single-dose regimens for M. genitalium, as this promotes resistance; use the extended 5-day regimen if treatment is indicated 3.
Do not confuse M. hominis with M. genitalium. M. hominis does not require treatment in asymptomatic men and is not a urethral pathogen 6.
Testing Recommendations for Symptomatic Patients
Always test for N. gonorrhoeae and C. trachomatis concurrently, as co-infections are common 8, 4.
Perform syphilis serology and offer HIV testing with counseling for all patients with suspected STIs 9, 4.
Macrolide resistance testing should be performed when available to guide appropriate therapy and avoid treatment failures 3, 2.